 |
|||||||||
 |
 |
 |
 |
||||||
Unicancer Approves Purchase of MagnetTx’s Aurora-RT LinacMR system by individual Unicancer sites
Edmonton, Alberta – TheNewswire – October 30, 2024 – MagnetTx Oncology Solutions Ltd. (“MagnetTx”), the designer, manufacturer, and marketer of the cutting-edge Aurora-RT LinacMR system, is pleased to announce that it has, together with its partner Seemed France, been awarded approved supplier status with Unicancer, a network of cancer centres in France, treating more than 540,000 cancer patients per year.
Unicancer is the only French hospital federation fully dedicated to the fight against cancer. Through its health cooperation group, Unicancer is also the only national hospital network exclusively specialized in oncology. It brings together 18 French Comprehensive Cancer Centres and two affiliated members, all offering a public service and playing a major role in healthcare and research in France.
“For MagnetTx to obtain approved supplier status with Unicancer, the Unicancer team has evaluated and accepted the Aurora-RT LinacMR system for purchase by any of Unicancer’s owned and affiliated cancer centres,” says Mike Cogswell, President and CEO of MagnetTx. “This means each of the individual centres may purchase an Aurora-RT LinacMR system from MagnetTx, as the need arises at each centre, without going through a lengthy tender process.”
The Aurora-RT is a new generation LinacMR system that allows imaging while treating the patient and adapting treatment to the anatomic changes. The Aurora-RT is the first system to use a parallel coplanar superconductive 0,5 Tesla magnet, virtually eliminating beam disturbance and Electron Return Effect (ERE) and Electron Streaming Effect (ESE), typical with other perpendicular magnet systems. Due to its unique ultra large 110 cm bore, and laterally moving couch, the Aurora-RT also allows treatment to a wider range of cancer patients, including full breast treatments.
With a potential throughput of 20-30 patients per day (variable with the patient mix), the Aurora-RT offers a solution to the primary concern of first generation linac-MR users – providing advanced treatment quality at an economical operating cost. Installed through the door or maze of a regular bunker, the Aurora-RT also allows additional economic advantages as it does not require liquid helium or quenching.
“The Aurora-RT is the new generation of MRI guided Linac, delivering the highest ratio of clinical benefit to cost,” says Jean-Luc Devleeschauwer, CCO at MagnetTx. “We are proud to have been selected by Unicancer for the benefit of all cancer patients in France and will work with our partner Seemed France to ensure that the technology is widely adopted.”
About MagnetTx
MagnetTx Oncology Solutions Ltd. is a Canadian-based company that develops global pioneering technology. MagnetTx has combined a linear accelerator (Linac), with real-time (concurrent) magnetic resonance imaging (MRI) to deliver radiotherapy to cancer patients. Our goal is to substantially reduce radiation treatment margins and improve cancer patient outcomes with fewer adverse side effects. Our first device is the groundbreaking Aurora-RT™.
Media contact:
Jessica Cogswell: [email protected]
Investor relations contact:
Roger Jewett, CFO
Commercial contact:
Jean-Luc Devleeschauwer
Copyright (c) 2024 TheNewswire – All rights reserved.
